- * Have given their agreement to take part in the observational registry after being informed in writing of the purposes of the study and after their data have been recorded (parent's agreement for minor patients);
- * Be suffering from haemophilia A and being treated or having been treated with Afstyla® long term prophylactically, on demand or preventatively for a surgical procedure;
- * Absence of inhibitor and/or treatment for immune tolerance at the time of inclusion
Haemophilia A
Register of Patients With haEmophilia A tReated With Afstyla®
NCT04675541 | PHASE 3 | OBSERVATIONAL
Record real life data of patients with Hemophilia A and treated with Afstyla® to assess the effectiveness and the safety of the treatment used as prophylaxis, prevention of bleeding (e.g. surgery) or on-demand treatment during 3 years after patient inclusion
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
CHU Brest
Brest,France
CHU Caen
Caen,France
CHU Chambry
Chambéry,France
CHU ClermontFerrand
Clermont-Ferrand,France
Hpital Simone Veil
Eaubonne,France
Hpital Mignot
Le Chesnay,France
CRCMHC Hpital Kremlin Bictre
Le Kremlin-Bicêtre,France
CHRU Lille
Lille,France
CHU Limoges
Limoges,France
CHU Montpellier
Montpellier,France
CHU Nantes
Nantes,France
Hpital Necker
Paris,France
CHU Rennes
Rennes,France
CHU Rouen
Rouen,France
CHU SaintEtienne
Saint-Étienne,France
Hpital Hautepierre
Strasbourg,France
CHRU de Tours
Tours,France,37044
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov